POC(Point of Care) 감염증 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Point of Care Infectious Disease Testing Market size is expected to reach USD 28.51 Billion in 2034 from USD 18.42 Billion (2025) growing at a CAGR of 4.97% during 2026-2034.

The global point of care (POC) infectious disease testing market is poised for significant growth, driven by the increasing demand for rapid and accurate diagnostic solutions in the face of rising infectious diseases. The COVID-19 pandemic has underscored the critical need for timely testing to control outbreaks and manage public health effectively. POC testing offers the advantage of delivering results within minutes, enabling healthcare providers to make informed decisions quickly and initiate appropriate treatment. As the focus on early detection and prevention of infectious diseases intensifies, the adoption of POC testing solutions is expected to accelerate, fostering innovation and investment in this vital market.

Moreover, advancements in technology are set to transform the POC infectious disease testing landscape. The integration of molecular diagnostics, microfluidics, and biosensors is enhancing the sensitivity and specificity of tests, allowing for the detection of a wide range of pathogens, including bacteria, viruses, and parasites. Additionally, the development of user-friendly devices that can be operated in various settings, from clinics to remote locations, is expanding access to testing. As healthcare systems increasingly prioritize decentralized testing approaches, the demand for innovative POC solutions that can deliver accurate results in real-time will continue to rise.

In addition, the growing emphasis on personalized medicine and the increasing focus on global health initiatives are expected to shape the future of the POC infectious disease testing market . As healthcare providers seek to tailor treatments to individual patient needs, the demand for rapid diagnostic tools that can inform clinical decisions is becoming paramount. POC testing aligns with this trend by enabling healthcare professionals to quickly assess a patient's condition and adjust treatment plans accordingly. Furthermore, global health initiatives aimed at combating infectious diseases, particularly in low-resource settings, are driving investments in POC testing technologies that can be deployed in diverse environments. Collaborative efforts between diagnostic manufacturers, healthcare organizations, and public health agencies will be essential in advancing these solutions, ensuring that the POC infectious disease testing market remains agile and responsive to emerging health challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Lateral Flow Immunoassay
• Agglutination Test
• Flow-Through Test/Immunoconcentration Assay
• Molecular Diagnostics
• Others

By Disease

• HIV POC
• Clostridium Difficile Poc
• HBV POC
• Pneumonia Or Streptococcus Associated Infections
• Respiratory Syncytial Virus (Rsv) POC
• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB & Drug-Resistant Tb Poc
• HSV POC
• Covid-19
• Others

By End Use

• Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

COMPANIES PROFILED

• Abbott, Thermo Fisher Scientific Inc, F HoffmannLa Roche Ltd, Siemens Healthineers, Becton, Dickinson Company, Chembio Diagnostics Inc, Trinity Biotech, Cardinal Health, Quest Diagnostics Incorporated, BioRad Laboratories Inc, bioMrieux SA, Sight Diagnostics Ltd, Gene POC, Trivitron Healthcare, OJBio Ltd, OrthoClinical Diagnostics

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Lateral Flow Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Agglutination Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Flow-Through Test/Immunoconcentration Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY DISEASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. HIV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clostridium Difficile Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HBV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Pneumonia Or Streptococcus Associated Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Respiratory Syncytial Virus (Rsv) POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. HPV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Influenza/Flu POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. HCV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. MRSA POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. TB & Drug-Resistant Tb Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. HSV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Covid-19 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.14. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Assisted Living Healthcare Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Laboratory Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Disease
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Disease
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Disease
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Disease
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Disease
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Siemens Healthineers
  • 9.2.5 Becton
  • 9.2.6 Dickinson & Company
  • 9.2.7 Chembio Diagnostics Inc
  • 9.2.8 Trinity Biotech
  • 9.2.9 Cardinal Health
  • 9.2.10 Quest Diagnostics Incorporated
  • 9.2.11 Bio-Rad Laboratories Inc
  • 9.2.12 BioMAfA(C)Rieux SA
  • 9.2.13 Sight Diagnostics Ltd
  • 9.2.14 Gene POC
  • 9.2.15 Trivitron Healthcare
  • 9.2.16 OJ-Bio Ltd
  • 9.2.17 Ortho-Clinical Diagnostics